* qt interval prolongation * imminence of orotracheal intubation (intubation prediction in the first 4 hours after randomization) * women who are pregnant or breastfeeding * corticosteroid allergy or intolerance * chronic corticosteroid users (prednisone equivalent \> 10 mg daily) * patients diagnosed with cancer with increased bleeding potential * patients in hemodialysis * history of peptic ulcer * herpes zoster infection * history or active treatment of tuberculosis * systemic fungal infection * use of anticoagulation due to previous pathology * glaucoma * live virus vaccine up to 90 days before randomization * known coagulopathy or thrombocytopenia (\<40,000/mm3) or hypofibrinogenemia (\< 50 mg/dl) * recent bleeding * another limiting comorbidity for administering the therapies provided for in this protocol in in researcher's opinion

* qt interval prolongation * imminence of orotracheal intubation (intubation prediction in the first 4 hours after randomization) * women who are pregnant or breastfeeding * corticosteroid allergy or intolerance * chronic corticosteroid users (prednisone equivalent \> 10 mg daily) * patients diagnosed with cancer with increased bleeding potential * patients in hemodialysis * history of peptic ulcer * herpes zoster infection * history or active treatment of tuberculosis * systemic fungal infection * use of anticoagulation due to previous pathology * glaucoma * live virus vaccine up to 90 days before randomization * known coagulopathy or thrombocytopenia (\<40,000/mm3) or hypofibrinogenemia (\< 50 mg/dl) * recent bleeding * another limiting comorbidity for administering the therapies provided for in this protocol in in researcher's opinion

- qt interval prolongation - imminence of orotracheal intubation (intubation prediction in the first 4 hours after randomization) - women who are pregnant or breastfeeding - corticosteroid allergy or intolerance - chronic corticosteroid users (prednisone equivalent > 10 mg daily) - patients diagnosed with cancer with increased bleeding potential - patients in hemodialysis - history of peptic ulcer - herpes zoster infection - history or active treatment of tuberculosis - systemic fungal infection - use of anticoagulation due to previous pathology - glaucoma - live virus vaccine up to 90 days before randomization - known coagulopathy or thrombocytopenia (<40,000/mm3) or hypofibrinogenemia (< 50 mg/dl) - recent bleeding - another limiting comorbidity for administering the therapies provided for in this protocol in in researcher's opinion

- qt interval prolongation - imminence of orotracheal intubation (intubation prediction in the first 4 hours after randomization) - women who are pregnant or breastfeeding - corticosteroid allergy or intolerance - chronic corticosteroid users (prednisone equivalent > 10 mg daily) - patients diagnosed with cancer with increased bleeding potential - patients in hemodialysis - history of peptic ulcer - herpes zoster infection - history or active treatment of tuberculosis - systemic fungal infection - use of anticoagulation due to previous pathology - glaucoma - live virus vaccine up to 90 days before randomization - known coagulopathy or thrombocytopenia (<40,000/mm3) or hypofibrinogenemia (< 50 mg/dl) - recent bleeding - another limiting comorbidity for administering the therapies provided for in this protocol in in researcher's opinion